Company news
Marizyme, Inc. (OTC:MRZM) news
Marizyme, Inc. news releases on 6ix. Latest, Apr 16, 2024: Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization…
Press releases & updates
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
April 15, 2024
Marizyme CEO Delivers Business Update
October 22, 2023
The Watchlist by The Market Herald Releases New Interviews with Marizyme, Regenx, BuildDirect, and Three Sixty Solar Discussing Their Latest News
October 5, 2023
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
October 5, 2023
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products
May 9, 2023
Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office
January 5, 2022
Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing
December 23, 2021
Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress
December 3, 2021
Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories
December 3, 2021
Marizyme is Pleased to Announce the Appointment of David Barthel as CEO
November 16, 2021
Marizyme, Inc. Issues Letter to Shareholders
March 31, 2021
Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera
March 4, 2021
Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf to Board
February 4, 2021
Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems
February 1, 2021
Marizyme Announces Approval for DuraGraft® in India
January 14, 2021
Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf
January 11, 2021
Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021"
January 7, 2021
Marizyme, Inc. Expands Executive Team, Board of Directors
December 4, 2020
Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors
November 6, 2020
Marizyme and SBH Nutrition Science Agree to Develop Krillase(R) Based Dental Products for Pets
October 26, 2020
Marizyme Announces European DuraGraft(R) Registry Results Presented at the European Association for Cardio-Thoracic Surgery (EACTS) 34th Annual Virtual Meeting
October 8, 2020
Univest Securities, LLC. Announces Closing of Somulation, Inc. Acquisition and $7 Million Private Placement for its Client Marizyme, Inc. (OTC: MRZM)
September 29, 2020
Marizyme, Inc. Completes Acquisition of Somahlution, Inc. and Raises $7.0 Million in Private Placement
September 28, 2020
Marizyme, Inc., Engages Dr. Pamela Milla as Advisor to Begin Distribution in South America
April 25, 2020
Marizyme and Somahlution Announce Agreement with Leipzig Heart Center to Use DuraGraft in Patients undergoing Coronary Artery Bypass Surgery
April 7, 2020
Marizyme, Inc. Hires Ralph Makar as Chief Executive Officer
February 24, 2020
Duragraft Receives SGK National Reimbursement in Turkey
February 17, 2020
Marizyme, Inc. Agrees to Acquire All Assets of Somahlution
December 16, 2019
Marizyme, Inc., Agrees to Distribute Somahlution's DuraGraft Products in South America and Mexico
October 11, 2019
Marizyme, Inc., Agrees to Distribute Somahlution’s DuraGraft Products in South America and Mexico
October 10, 2019
OTC Markets Group Welcomes New OTCQB Companies – July 31
July 31, 2019